🟧A general‑population overview with NET‑specific considerations where relevant.
What is Vitamin A?
Vitamin A refers to a group of fat‑soluble retinoids (retinol, retinal, retinoic acid). These are the active forms used by the body. Plant pigments such as beta‑carotene are pro‑vitamin A carotenoids that must be converted into retinol before use.
What does Vitamin A do?
- Supports vision, especially low‑light vision
- Maintains epithelial and mucosal surfaces
- Supports immune function
- Regulates gene expression and cell differentiation
- Assists with iron mobilisation
Deficiency
Vitamin A deficiency is uncommon in high‑income countries but can occur with malabsorption, pancreatic insufficiency, bile acid loss, liver disease, or very low intake.
- Night blindness
- Dry eyes and dry skin
- Increased susceptibility to infections
- Conjunctival or corneal changes in severe deficiency
Testing
The standard test is serum retinol. It is reliable for moderate–severe deficiency but less sensitive for early depletion. Levels may be influenced by inflammation and liver function.
Sources
- Preformed Vitamin A (retinol) — liver, dairy, eggs, oily fish, fortified foods
- Pro‑vitamin A carotenoids — carrots, sweet potatoes, leafy greens, peppers, mango, papaya, apricots
Carotenoid conversion varies widely and is reduced in malabsorption, pancreatic insufficiency, and low‑fat diets.
Carotenoids
Carotenoids are plant pigments that can be converted into retinol. They are safe and contribute to overall Vitamin A intake, but:
- They are not active Vitamin A
- Conversion is variable and often reduced in malabsorption
- They cannot reliably correct deficiency
- They do not cause toxicity
Supplements
- Retinol/retinyl esters — effective for correcting deficiency; risk of toxicity at high doses
- Carotenoids — safer but less reliable in malabsorption
Toxicity
Only retinol causes toxicity. Carotenoids do not.
- Acute toxicity: neurological symptoms
- Chronic toxicity: liver injury, bone effects, skin changes, teratogenicity
NET‑Specific Considerations
Vitamin A deficiency is more likely in NET patients with:
- Pancreatic NETs with exocrine insufficiency
- Ileal NETs or ileal resection → bile acid loss
- Chronic diarrhoea or steatorrhoea
- Somatostatin analogue therapy
- Liver metastases affecting storage
Deficiency often co‑exists with low Vitamins D, E, and K.
Personal note
Always speak to your specialist before taking vitamin and mineral supplements — you may not need them if your levels are normal. Many NET patients assume Vitamin and Mineral deficiencies are inevitable, but with proper monitoring and management (including PERT where appropriate), levels can remain stable. A warning on taking vitamins and minerals generally. I very often see patients discussing this on my public pages and in my private group. I just wanted to say that you must always take advice from a professional, just because one patient takes a vitamin ‘x’ or mineral ‘y’, that does not mean you should take it too.
References Used
- NHS Vitamin A Guidance
- NIH Office of Dietary Supplements – Vitamin A Fact Sheet
- ESMO – Reducing deficiencies of fat-soluble vitamins, vitamin B12, and vitamin B3 in patients with neuroendocrine tumors treated with somatostatin analogues – L.D. de Hosson, S. Bunskoek, J. Stelwagen, B. Sijtema, S. Huitema, M. van Faassen, G.H. de Bock, D.J.A. de Groot, M.J.E. Campmans-Kuijpers, I.P. Kema, E.G.E. de Vries, A.M.E. Walenkamp, Volume 4, 2025, 100032, ISSN 3050-4619, https://doi.org/10.1016/j.esmorc.2025.100032. (https://www.sciencedirect.com/science/article/pii/S3050461925000310)
See other fat soluble vitamins here:
Vitamin D – click here
Vitamin E – click here
Vitamin K – click here
Thanks for reading.
Ronny
Disclaimer
I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me. Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional. Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.
Click here and answer all questions to join my private Facebook group
Ronny
Check out my WEGO Health Awards
Check out my Glossary of Terms – click here
Please Share this post for Neuroendocrine Cancer awareness and to help another patient
- Ronny Allan’s Newsletter covering October 2026
Summary of October 2026 on RonnyAllan.NET October was similar to the other months of this year but like July and August, views are down on the previous two months due to 3 weeks of holiday. Still a reasonable blog performance – I can’t complain. Still managed to cover 3 new US FDA approvals! I had… Read more: Ronny Allan’s Newsletter covering October 2026 - I made it to 71!
I started doing the “Piss off cancer” or “I made it” series when I got to 65, mainly because I initially thought I wouldn’t make that age. I was 54 years and 9 months old at diagnosis on 26th July 2010. For the first few months, I had no idea what the outcome would be. … Read more: I made it to 71! - Neuroendocrine Tumours (NET) – Does rising incidence and prevalence need more research, funding and resources?
The title of this blog is the form of a rhetorical question. Neuroendocrine Tumours (NET) – Does rising incidence and prevalence need more research, funding and resources? I guess if you ask any patient, the answer is a resounding YES. I also very much guess that many doctors would repeat that answer. And some are… Read more: Neuroendocrine Tumours (NET) – Does rising incidence and prevalence need more research, funding and resources? - Ronny Allan’s Newsletter covering September 2026
Summary of September 2026 on RonnyAllan.NET September was similar to the other months of this year but like July and August, views are down on the previous two months due to 3 weeks of holiday. Still a reasonable blog performance – I can’t complain. Still managed to cover 3 new US FDA approvals! I had… Read more: Ronny Allan’s Newsletter covering September 2026 - Amneal Lanreotide Approved by US FDA
Amneal launches first CGT‑designated U.S. generic lanreotide — what NET patients need to know Amneal has launched the first Competitive Generic Therapy (CGT)‑designated U.S. generic for lanreotide, a major milestone in a market long dominated by Ipsen’s Somatuline® Depot. The product — lanreotide injection 120 mg/0.5 mL in a sterile single‑dose prefilled syringe —… Read more: Amneal Lanreotide Approved by US FDA - Ronny Allan’s Newsletter covering August 2026
Summary of August 2026 on RonnyAllan.NET August was similar to the other months of this year but like July, views are down on the previous two months due to 50% of the month spent on holiday. Still a reasonable blog performance – I can’t complain. Other key targets met were three more editions of the Spotlight… Read more: Ronny Allan’s Newsletter covering August 2026 - External Beam Radiation Therapy (EBRT) for Neuroendocrine Neoplasms
Disclaimer: The information in this section is for education only and does not represent a standard care pathway or service. These treatments are not suitable for everyone, and careful patient selection by an experienced multidisciplinary team is essential. Always discuss your individual situation with your own specialist team. External Beam Radiation Therapy (EBRT) is… Read more: External Beam Radiation Therapy (EBRT) for Neuroendocrine Neoplasms - 2026 Surveillance Update from Ronny Allan: “See you in 12 months”
It’s only a couple of weeks since I celebrated my 16th year since diagnosis of metastatic small intestine Neuroendocrine Tumour (NET) at Grade 2 on 26th July 2010. Thinking back to that period of my life, I’m happy but also slightly amazed to be celebrating such a long milestone having been diagnosed with cancer at… Read more: 2026 Surveillance Update from Ronny Allan: “See you in 12 months” - Spotlight: Selenium in Neuroendocrine Tumours (NETs)
Before you read this This information is designed to help you understand how vitamins and minerals work in the body and how certain NET‑related factors might influence them. It is not a substitute for personalised medical advice. Every NET patient is different — tumour type, treatments, surgery, symptoms, and nutritional needs vary widely. If you… Read more: Spotlight: Selenium in Neuroendocrine Tumours (NETs) - Spotlight: Potassium in Neuroendocrine Tumours (NETs)
Before you read this This information is designed to help you understand how vitamins and minerals work in the body and how certain NET-related factors might affect them. It is not a substitute for personalised medical advice. Every NET patient is different — tumour type, treatments, surgery, symptoms, and nutritional needs can vary widely.… Read more: Spotlight: Potassium in Neuroendocrine Tumours (NETs) - Spotlight: Magnesium in Neuroendocrine Tumours (NETs)
Before you read thisThis information is designed to help you understand how vitamins and minerals work in the body and how certain NET-related factors might affect them. It is not a substitute for personalised medical advice. Every NET patient is different — tumour type, treatments, surgery, symptoms, and nutritional needs can vary widely. If you… Read more: Spotlight: Magnesium in Neuroendocrine Tumours (NETs) - Ronny Allan’s Newsletter covering July 2026
Summary of July 2026 on RonnyAllan.NET July was similar to the other months of this year but views down on the previous two months due to 50% of the month spent on holiday. Still a reasonable blog performance. Other key targets met were three more editions of the Spotlight series on vitamins and minerals. See… Read more: Ronny Allan’s Newsletter covering July 2026 - 16 years since diagnosis, I’m still here

I finally made 16 years since I was diagnosed on 26th July 2010. A milestone I was not certain at the time I would reach. However, as things progressed, as treatment was administered, and as I got used to living with Neuroendocrine Cancer, I eventually became more confident this was a possibility with the help […]
- Spotlight on Cushing’s Syndrome in Neuroendocrine Neoplasms
Intro Cushing’s syndrome is one of the most challenging hormonal complications seen in people with neuroendocrine neoplasms (NENs). It can be subtle, severe, or even life‑threatening — and it is often misunderstood. Many patients struggle for months or years before receiving a correct diagnosis, partly because the symptoms overlap with everyday conditions such as weight… Read more: Spotlight on Cushing’s Syndrome in Neuroendocrine Neoplasms - 14th July 2026 – Ronny Allan hits 3 million blog views!
Today, 14th July 2026, I can confirm the 3 million views milestone has been reached. MASSIVE THANKS to you guys for reading and sharing. When I first set up this blog in April 2014, it was just to help spread awareness (….and collect a few pennies) whilst I was walking the 84 miles of… Read more: 14th July 2026 – Ronny Allan hits 3 million blog views! - Spotlight: Zinc in Neuroendocrine Tumours (NETs)
Before you read thisThis information is designed to help you understand how vitamins work in the body and how certain NET-related factors might affect them. It is not a substitute for personalised medical advice. Every NET patient is different — tumour type, treatments, surgery, symptoms, and nutritional needs can vary widely. If you have… Read more: Spotlight: Zinc in Neuroendocrine Tumours (NETs)
Discover more from Ronny Allan - Living with Neuroendocrine Cancer
Subscribe to get the latest posts sent to your email.


